---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000067"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:40:37.406960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia extends vadadustat supply agreement with STA through 2032

## Summary
- Amendment #1 to Supply Agreement with STA extended term to January 1, 2032.
- Volume-based pricing structure and other provisions related to vadadustat drug product amended.
- Original Supply Agreement entered February 10, 2021 for manufacturing of vadadustat.

## SEC filing metadata
- accession: 0001517022-24-000067
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/0001517022-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/akba-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000067
- JSON: https://secwatch.observer/filing/0001517022-24-000067.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.